Diabetic Neuropathic Pain Therapeutics Pipeline Review H1 2016 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Diabetic Neuropathic Pain - Pipeline Review, H1 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Diabetic Neuropathic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Neuropathic Pain and special features on late-stage and discontinued projects.

The report enhances decision-making capabilities and helps to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MoAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Diabetic Neuropathic Pain Overview
  3. Therapeutics Development
  4. Pipeline Products for Diabetic Neuropathic Pain - Overview
  5. Pipeline Products for Diabetic Neuropathic Pain - Comparative Analysis
  6. Diabetic Neuropathic Pain - Therapeutics under Development by Companies
  7. Diabetic Neuropathic Pain - Therapeutics under Investigation by Universities/Institutes
  8. Diabetic Neuropathic Pain Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Diabetic Neuropathic Pain - Products under Development by Companies
  13. Diabetic Neuropathic Pain - Products under Investigation by Universities/Institutes
  14. Diabetic Neuropathic Pain - Companies Involved in Therapeutics Development
  • Astellas Pharma Inc.
  • BioDelivery Sciences International, Inc.
  • Boehringer Ingelheim GmbH
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • Glenmark Pharmaceuticals Ltd.
  • Hydra Biosciences, Inc.
  • Immune Pharmaceuticals Inc.
  • Laboratorios Del Dr. Esteve S.A.
  • Lohocla Research Corporation
  • Mertiva AB
  • Novaremed
  • PeriphaGen, Inc.
  • Pharmaleads
  • Prismic Pharmaceuticals, Inc.
  • Relmada Therapeutics, Inc.
  • Sphaera Pharma Pvt. Ltd.
  • Theravasc, Inc.

For more information visit http://www.researchandmarkets.com/research/zfl5xf/diabetic

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716